BMY Stock — Price, Charts & Analysis

Bristol-Myers Squibb Company (BMY) has a trailing P/E of 14.83x and a forward P/E of 10.27x. This places BMY in a lower earnings multiple territory based on the valuation data currently available on Worldtickers.

BMY trades with 14.83x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether BMY looks overvalued or undervalued.

BMY's P/E of 14.83x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

BMY's trailing EPS is $4.54 and forward EPS is $6.56. Reported earnings growth is 153.10%, which helps show current profit momentum.

EPS, or earnings per share, shows how much profit Bristol-Myers Squibb Company generated for each share. BMY's trailing EPS is $4.54, and investors usually prefer EPS that is positive and growing over time.

Bristol-Myers Squibb Company has a market cap of $137.55B, making BMY a large-cap stock based on the current market value shown on Worldtickers.

BMY's latest stock price on Worldtickers is $67.34. The latest move is $1.86 or 2.85%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

BMY's quote includes a latest price of $67.34. The market open is $65.79. Previous close is $65.47. The intraday range is $65.13 to $67.55.

BMY is up in the latest quote, with a move of $1.86 or 2.85%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

BMY generated $49.19B in trailing revenue. Revenue growth is 5.70%, which helps show whether demand is expanding or slowing.

BMY's revenue growth is 5.70%, which is a positive demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

Yes, BMY shows positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is $9.28B.

Gross margin is 71.66%. Margins show how efficiently Bristol-Myers Squibb Company turns revenue into profit.

Bristol-Myers Squibb Company carries $45.05B and holds $11.07B in cash.

BMY holds $11.07B on its balance sheet.

BMY's book value per share is $10.93.

Yes, Bristol-Myers Squibb Company pays a dividend of $2.52 per share annually. The dividend yield is 385.00%. The payout ratio is 55.29%.

BMY's dividend yield is 385.00%. Its payout ratio is 55.29%, which helps judge dividend sustainability. Dividend investors usually prefer a reasonable yield, consistent cash flow, and a payout ratio that leaves room for reinvestment.

Worldtickers does not currently show a confirmed next ex-dividend date for BMY. The page does show dividend rate and yield when available, and investors should confirm record and payment dates through Bristol-Myers Squibb Company's investor relations materials.

BMY's five-year average dividend yield is 396.00%. Use this alongside current yield, payout ratio, and cash flow to understand whether today's dividend looks high or low versus recent history.

Institutions hold 84.69% of BMY shares. Insiders hold 0.10% of shares. Ownership mix helps investors understand how much of Bristol-Myers Squibb Company is held by professional investors and company insiders.

BMY has 2.04B shares outstanding. Float shares are 2.04B. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for BMY, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for BMY is $6.56. Earnings growth is 153.10%. Revenue growth is 5.70%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

BMY's trailing EPS is $4.54. Forward EPS is $6.56. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

BMY is in the Healthcare sector. Its earnings multiple is 14.83x. Its latest displayed growth metric is 5.70%. Compare these figures with sector peers before deciding whether Bristol-Myers Squibb Company is stronger or weaker than average.

BMY trades at $67.34. The stock trades at 14.83x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Bristol-Myers Squibb Company's fundamentals.

BMY risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 0.23, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

BMY should be compared with companies in Drug Manufacturers - General. Its earnings multiple is 14.83x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Bristol-Myers Squibb Company (BMY) operates in Healthcare, specifically Drug Manufacturers - General. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to t

BMY trades on NYSE. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

BMY stock is priced in USD on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Bristol-Myers Squibb Company's official website listed on Worldtickers is www.bms.com/investors/Pages/home.aspx. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Bristol-Myers Squibb Company employs about 32.5K people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Bristol-Myers Squibb Company is headquartered in Princeton, NJ, United States. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

BMY is in the Healthcare sector and the Drug Manufacturers - General industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

BMY has traded between $42.52 and $68.64 over the past 52 weeks. At $67.34, it is 1.90% below the high and 58.36% above the low. The 52-week range helps gauge long-term price momentum.

BMY is above both its 50-day and 200-day moving averages, which is a common uptrend signal. Its 50-day moving average is $60.57 and its 200-day moving average is $57.14.

BMY's RSI is 63.08. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

BMY's latest RSI reading is 63.08, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for BMY is near $61.60. Key resistance is near $68.64. Breaks above resistance or below support can change the short-term technical setup.

BMY's nearest reported support level is $61.60. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

BMY's nearest reported resistance level is $68.64. A breakout above resistance can improve momentum, especially when volume confirms the move.

BMY trades about 12.45M shares daily on average. The latest displayed volume is 4.27M shares. Volume helps show liquidity and whether trading interest is unusually high or low.

BMY's MACD is 0.03, which is a positive momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

BMY is above both its 50-day and 200-day moving averages, which is a common uptrend signal. RSI is 63.08 (neutral). MACD is bullish. Nearest support is around $61.60. Resistance is around $68.64. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is $64.74 (3.74% from price). MA50 is $60.57 (10.88% from price). MA200 is $57.14 (17.55% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. BMY's MA20 is $64.74. MA50 is $60.57. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

BMY's pivot is near $66.15. Support is near $61.60. Resistance is near $68.64. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for BMY is near $63.03. These levels help define risk and possible follow-through zones after a breakout or breakdown.

BMY's Bollinger range is roughly $62.21 to $67.28. Band width is near 7.83%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

BMY's ATR-based typical daily range is about 2.68%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 4.27M shares. Average volume is about 12.45M shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

BMY's all-time high shown on Worldtickers is $81.44. Its all-time low is $0.91. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

BMY has a beta of 0.23, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.